trastuzumab deruxtecan
AstraZeneca Advancing Plan to Launch Biomarker-Driven Drugs as Alternative to Chemo in Breast Cancer
Premium
The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.
AstraZeneca, Daiichi Sankyo's Enhertu BLA in HER2-Low, Ultralow Breast Cancer Gets FDA Priority Review
The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.
The results, published in Nature Medicine, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line option for metastatic breast cancer, experts said.
AstraZeneca Reports Encouraging Uptake of New Breast Cancer Drug Truqap in First Half of 2024
Premium
Despite a disappointing Phase III failure in triple-negative breast cancer, Truqap sales were strong in patients with biomarker-altered hormone-sensitive disease.
AstraZeneca Looks to Bolster Radiopharmaceutical Capacity as Cancer Drugs Help Q1 Revenue Growth
Premium
The company is hoping to gain a competitive edge in the radio-conjugate space with the acquisition of Fusion Pharmaceuticals.